Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients continue to progress despite multiple anti-HER2-targeted treatments. A number of studies have found that Pyrotinib, a small-molecule pan-ErbB receptor tyrosine kinase inhibitor (TKI), is effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenyu, Yang, Jixin, Zhang, Ze, Xu, Dongdong, Li, Nanlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007886/
https://www.ncbi.nlm.nih.gov/pubmed/36915587
http://dx.doi.org/10.21037/tcr-22-1746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007886/
https://www.ncbi.nlm.nih.gov/pubmed/36915587
http://dx.doi.org/10.21037/tcr-22-1746

Ejemplares similares